Search

This review summarizes the current knowledge of radiation-induced nausea and vomiting (RINV), which occurs in ap-proximately 50% of patients undergoing radiotherapy. Poor control of the symptoms may result in dehydration and electrolyte disturbances leading to delay or even disruption of the planned schedule, which in turn results in decreased disease control. Patients report RINV as distressing symp-toms, and under-treatment is a major problem. Evidence-based antiemetic guidelines have been developed, but lack of adherence is a barrier to improvement of symptom control and quality of life during radiotherapy. more...

Nausea and vomiting are a persistent burden on cancer patients undergoing antineoplastic therapy, and adherence to guideline-specific prophylactic therapy is essential to minimise the risk. Nausea is more challenging to prevent than vomiting. This review summarises the choices of relevant drugs. Olanzapine is effective against nausea, but sedation can be a problem. There seems to be no major differences in effect or tolerability between different serotonin receptor antagonists and different neurokinin receptor antagonists. Consequently, the choice of drug should be based on price, risk of interactions and simple administration. more...